1. Home
  2. INLX vs SNTI Comparison

INLX vs SNTI Comparison

Compare INLX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

HOLD

Current Price

$6.70

Market Cap

30.4M

Sector

Technology

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.87

Market Cap

29.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
SNTI
Founded
1996
2016
Country
United States
United States
Employees
98
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.4M
29.8M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
INLX
SNTI
Price
$6.70
$0.87
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
1.7K
179.4K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
$11,336.00
N/A
Revenue This Year
$16.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.45
$0.77
52 Week High
$14.57
$3.88

Technical Indicators

Market Signals
Indicator
INLX
SNTI
Relative Strength Index (RSI) 41.75 41.33
Support Level N/A $0.81
Resistance Level $8.12 $0.93
Average True Range (ATR) 0.29 0.08
MACD -0.02 -0.01
Stochastic Oscillator 18.66 4.61

Price Performance

Historical Comparison
INLX
SNTI

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: